{{Drugbox
| IUPAC_name = 2-Chloro-''N''-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
| image = Vismodegib2DACS.svg

<!--Clinical data-->
| pronounce = {{IPAc-en|ˌ|v|ɪ|s|m|oʊ|ˈ|d|ɛ|g|ɪ|b}} {{respell|VIS|moh|DEG|ib}}
| tradename =  Erivedge
| Drugs.com = {{Drugs.com|monograph|erivedge}}
| licence_EU = Erivedge
| licence_US = Vismodegib
| pregnancy_AU = X <ref>{{Drugs.com|pro|erivedge}}</ref>
| pregnancy_US = X <ref>{{Drugs.com|pro|erivedge}}</ref>
| pregnancy_category =  
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = [[Oral administration|By mouth]] ([[Capsule (pharmacy)|capsules]])

<!-- Pharmacokinetic data -->
| bioavailability = 31.8%
| protein_bound = >99%
| metabolism = <2% metabolised by [[CYP2C9]], [[CYP3A4]], [[CYP3A5]]
| elimination_half-life = 4 days (continuous use),<br/>12 days (single dose)
| excretion = Fecal (82%), Urinary (4.4%)

<!--Identifiers-->
| IUPHAR_ligand = 6975
| CAS_number = 879085-55-9
| ATC_prefix = L01
| ATC_suffix = XX43
| PubChem = 24776445
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 66903
| ChEMBL = 473417
| UNII = 25X868M3DS
| DrugBank = DB08828
| ChemSpiderID = 23337846
| KEGG = D09992
| synonyms = GDC-0449, RG-3616

<!--Chemical data-->
| C=19 | H=14 | Cl=2 | N=2 | O=3 | S=1 
| molecular_weight = 421.30 g/mol
| smiles = CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
| StdInChI = 1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)
| StdInChIKey = BPQMGSKTAYIVFO-UHFFFAOYSA-N
}}

'''Vismodegib''' (trade name '''Erivedge''' {{IPAc-en|ˈ|ɛr|ɪ|v|ɛ|dʒ}} {{respell|ERR|i-vej}}) is a [[pharmaceutical drug|drug]] for the treatment of [[basal-cell carcinoma]] (BCC). The approval of vismodegib on January 30, 2012, represents the first [[Hedgehog signaling pathway]] targeting agent to gain U.S. [[Food and Drug Administration]] (FDA) approval.<ref>{{cite web | title=Vismodegib, First Hedgehog Inhibitor, Approved for BCC Patients | url=http://www.onclive.com/web-exclusives/Vismodegib-First-Hedgehog-Inhibitor-Approved-for-BCC-Patients-}}</ref> The drug is also undergoing clinical trials for metastatic [[colorectal cancer]], [[small-cell lung cancer]], advanced [[stomach cancer]], [[pancreatic cancer]], [[medulloblastoma]] and [[chondrosarcoma]] {{as of |2011|6|lc=on}}.<ref name="Prous" /> The drug was developed by the [[biotechnology]]/[[pharmaceutical drug|pharmaceutical]] company [[Genentech]], which is headquartered at [[South San Francisco, California]], [[United States|USA]].

==Indication==
Vismodegib is indicated for patients with [[basal cell carcinoma]] (BCC) which has metastasized to other parts of the body, relapsed after surgery, or cannot be treated with surgery or radiation.<ref>{{cite web |title=FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma  | url=http://www.roche.com/media/media_releases/med-cor-2012-01-30.htm }}</ref><ref>{{cite book|last1=Lacroix|first1=Marc|title=Targeted Therapies in Cancer|date=2014|publisher=Nova Sciences Publishers|location=Hauppauge , NY|isbn=978-1-63321-687-7|url=https://www.novapublishers.com/catalog/product_info.php?products_id=50994}}</ref>

==Mechanism of action==
The substance acts as a [[cyclopamine]]-competitive [[receptor antagonist|antagonist]] of the [[smoothened]] receptor (SMO) which is part of the [[hedgehog signaling pathway]].<ref name="Prous" /> SMO inhibition causes the transcription factors [[GLI1]] and [[GLI2]] to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway.<ref>{{cite web | url=http://www.biooncology.com/pipeline-molecules/vismodegib/index.html | title=Vismodegib (GDC-0449) Smoothened Inhibitor - BioOncology}}</ref> This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas.<ref name="Spreitzer" />

==Side effects==
In clinical trials, common [[side effect|adverse effects]] included gastrointestinal disorders (nausea, vomiting, diarrhoea, constipation), muscle spasms, fatigue, hair loss, and [[dysgeusia]] (distortion of the sense of taste). The effects were mostly mild to moderate.<ref>{{Drugs.com|pro|erivedge}}</ref>

==See also==
* [[Cyclopamine]], a naturally occurring SMO antagonist

==References==
{{reflist|refs=
<ref name="Spreitzer">{{cite journal
 | author = H. Spreitzer
 | date = 4 July 2011
 | title = Neue Wirkstoffe – Vismodegib
 | journal = Österreichische Apothekerzeitung
 | issue = 14/2011
 | pages = 10
 | language = German
}}</ref>
<ref name="Prous">{{cite journal|url=http://www.prous.com/molecules/default.asp?ID=210|title=Molecule of the Month|date=June 2011}}</ref>
}}

== External links ==
* [http://www.erivedge.com/ Erivedge (vismodegib) Official Web Site]
* [http://www.nejm.org/doi/full/10.1056/NEJMoa1113713 Efficacy and Safety of Vismodegib]
* [http://www.cancer.gov/about-cancer/treatment/drugs/fda-vismodegib Food and Drug Administration (FDA) approved vismodegib]

{{Extracellular chemotherapeutic agents}}

[[Category:Benzanilides]]
[[Category:Chloroarenes]]
[[Category:Pyridines]]
[[Category:Sulfones]]
[[Category:Teratogens]]